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A CONNECTION between metal chela-
tion* and at least some types of cancer
was suggested by Furst (1963). Schubert
(1966) observed that metal chelation
apparently plays a definite role in the
cause and treatment of malignancy. The
effectiveness of quite a number of metal
complex compounds has now beendefinite-
ly established (Rosenberg, 1971; Williams,
1972; Cleare, 1974; Khan, 1977). In most
instances the compounds are neutral
platinum complexes of the type cis-
PtA2X2 (A = neutral unidentate ligand,
such as NH3; X _ charged ligand, such
as Cl-). More recently the "platinum-
pyrimidine blues" have been found to be
potent anti-tumour agents (Davidson et
al., 1975). However, little has been
reported on the screening of metal che-
lates as anti-tumour agents.
Certain dialkyldithiophosphate com-
plexes (I) have been reported to display
carcinostatic activity in the Walker 256
carcinosarcoma test. When R ethyl,
the values for T/C (reduction of tumour
in test animal compared to control
tumour) for the nickel and palladium
chelates were 45 and 16%, respectively,
yet the platinum chelate showed little
activity. Furthermore, when ethyl was
replaced by other alkyl groups, the
activity of the nickel and palladium
chelates was virtually zero (T/C 100),
indicating that minor changes in the ligand
markedly affect the activity (Livingstone
and Mihkelson, 1970).
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Anti-tumour activity has been reported
for some metal chelates of deriva-
tives of dithiocarbazic acid, H2NTNHCSSR
(Akbar Ali and Livinlgstone, 1974; Das
and Livingstone, 1975). The palladium
chelate (II) and the copper chelate (III)
were found to display cytostatic activity
in the 9KB test-a human epidermoid
carcinoma of the nasopharynx. Because
of these promising results we, in colla-
boration with the United States National
Cancer Institute, have undertaken a
systematic study of the anti-tumour
activity of transition metal chelates
of Schiff base ligands derived from
S-methyldithiocarbazate, H2NNHC(-S)
SCH3-
* A chelate is a metal complex in which one or more ligands (attachedl groups) are bound to the metal atom
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TABLE I. Screening Datafor Anti-tumour
Activity of Metal Chelates in the P388
Lymphocytic Leukaemia Test System in
Mice
Dose
Corn- range
ptonid R R' * (mg/kg)
NiL2 Mle Et 25 -400
PdL2 Me Et 0-8-200
PtL2 Me Et 12-5-200
CuL2 AMe Et 25 -400
ZnL2 Me Et 25 -400
NiL2 Me Prn 100 -400
PdL2 Me Prn 12-5-200
CuL2 MIe Prn 100 -400
ZnL2 Me Prn 100 -400
CuL2 Me Bun 100 -400
ZnL2 Me Bun 100 -400
PdL2 Me Buti 12 5-200
PtL2 Me Buii 6-2-200
P(dL2 Et Et 12-5-200
PtL2 Et Et 12-5 200
PdIL2 Prn pi.n 12-5-200
Pt,L2 Prn Prn 12-5-400
CuL2 Prn Prn 50 --200
ZnL2 Prn Pirn 50 -200
P(dL2 Bun Buln 12-5-400
CuL2 Bun Bun 6-2-400
CuL2 H pirn 1-5-200
CuL2 H CH3CH 12-5-200
=CH
PbIL2 Me Ph 12-5-200
PtL2 Me Ph 12-5-200
CuL2 Me Ph 100 -400
ZnL2 Mle Ph 100 -400
PdL2 Et Ph 12-5-400
PtL2 Et Ph 12-5-400
NiL2 Ph Ph 50 200
PdL2 Ph Ph 12-5-400
PtL2 Ph Ph 12 5-400
CuL2 Ph Ph 50 200
ZnL2 Ph Ph 50 200
NiL2 H C4H4N 6 2-200
PdL2 Me C4H3S 12 5- 400
PtL2 Me C4H38 12-5-400
CuL2 Me C4H3S 3-1-200
ZnL2 Me C4H3S 50 -200
NiL2 Me C4H30 12-5-400
PdL2 Me C4H30 12-5-400
PtL2 Me C4H:3O 100 -400
CuL2 Me C4H30 100 -400
ZnL2 AMe C4H30 50 -400
Opti-
mum
dose
100
6-2
12-5
50
100
50
200
100
100
12-5
25
12 5
100
25
12 5
100
50
100
12-5
12-5
100
12-5
12-5
100
200
200
12-5
400
12-5
100
12-5
400
12-5
6-2
50
12-5
25
400
200
100
T/C
at
Survi- optimum
vors dlosage
6/6 107
6/6 117
6/6 109
0/6 toxic
6/6 110
6/6 100
3/3 125
0/6 toxic
6/6 107
4/6 89
6/6 103
6/6 115
5/5 108
4/4 120
6/6 111
6/6 104
6/6 106
6/6 107
6/6 101
6/6 94
6/6 109
6/6 105
5/6 105
6/6 107
6/6 107
6/6 100
6/6 118
6/6 114
6/6 115
0/6 toxic
3/3 129
6/6 115
6/6 86
0/6 toxic
6/6 112
3/3 105
6/6 97
6/6 120
6/6 97
6/6 104
6/6 110
6/6 101
6/6 100
6/6 104
* Me = methyl; Et -ethyl; Prn = n-piopyl; Btln
o-buityl; BuLI iso-butyl; Ph = phen-yl; C4H4N -
2-pyrrolyl; C4H3S -2-thieniyl; C4H30 = 2-furyl.
R"S-
L = C=NN=C
R' >SCH3
The Schiff base ligands (IV), by the loss
of a proton from their tautomeric form
(V), can act as single negatively-charged
bidentate ligands coordinating to metal
ions via the mercapto sulphur and the
f-nitrogen atoms. The Schiff bases were
prepared with different R and R' groups
in order to ascertain whether slight modi-
fications in the structure of the ligand
would enhance the cytotoxic activity of
the metal chelates, and if so, what struc-
tural features are responsible for the
enhanced activity. Complexes of these
ligands with nickel(II), palladium(II),
platinum(II), copper(II), and zinc(II)
were prepared. The syntheses of the
Schiff-base ligands and the metal chelates
have been reported (Das and Livingstone,
1976).
The screening data in the P388 lympho-
cytic leukaemia test system in mice for
44 metal chelates are listed in Table I.
The mice were inoculated in the peritoneal
cavity with an ascitic tumour at a level
of 106 cells. One day after the inoculation
the mice were injected i.p. with a saline
suspension of the metal chelate. A total of
9 injections were given at daily intervals.
Toxicity was evaluated 4 days after the
first day of injection. The survivors were
recorded on this day as a measure of drug
toxicity. The results of the screening were
evaluated after 30 days on the basis of
survival. In a "survival tumour system"
the increase in survival of treated animals
over controls is expressed as T/C (0%): a
T/C value of 100 means that the drug has
no effect of either increasing or decreasing
the tumour. A T/C value > 125 indicates
that the compound is considered worthy
of testing in other tumour systems.
Only 4 of the metal chelates tested were
found to be toxic. Most of them showed
some activity, but 6 have T/C values >
115 at the optimum dosage, which can be
regarded as indicating significant activity.
Ofthese 6, 4 arepalladium, 1 is a platinum,
and 1 is a copper chelate. Furthermore, 2
palladiumchelateshave T/C values > 125,
indicating that further testing in other
tumour systems is warranted. The greater
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incidence of activity among the palladium
chelates may not be significant in such a
small sample of compounds but, taken
together with 2 previous examples of
activity of palladium chelates (Living-
stone and Mihkelson, 1970; Akbar Ali and
Livingstone, 1974), this seems to indicate
that palladium chelates are more likely to
be effective anti-tumour agents than
chelates of other metals, at least with
sulphur donor atoms.
We have extended our study to metal
chelates of tridentate Schiff bases (VI)
derived from S-methyldithiocarbazate.
These Schiff bases, by the loss of a proton
from their tautomeric form (VII), can
behave as singly negatively charged tri-
dentate ligands coordinating to metal ions
via the mercapto sulphur, the f-nitrogen,
and the pyridine nitrogen atoms.
Complexes of the Schiff bases (VI) with
rhodium(III), nickel(II), palladium(II),
platinum(II), copper(II), and zinc(II)
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TABLE II. Screening DataforAnti-tumour
Activity of Mletal Chelates in the P388
Lymphocytic Leukaemia Test System in
Mice
Compound
NiLCI *
PdLC1
ZiiLNO3
NiLCI
PtLCI
CuLCI
RhLC12H20
NILCI
NiLNO3
PdLCI
PtLCI
CuLCl
ZnLNO3
RhLCI2H20
P(ILCI
C.uLCI
ZnLN03
Dose Opti-
range mum
R 1' (mg/kg) dose
H H 3 2-200 6-2
H H 12 5-200 2;5
H H 3-1-200 12-5
Me H 1-6-200 6-2
Ale H :31-200 6 2
Me H 0 8-200 0 8
Ph HX 50 -200 50
Ph H 3-1-200 6 2
Ph H 50 -200 200
Ph H 12 5-200 50
Ph H 3-1-200 100
Ph H 0 8200 1-6
Ph H 6-2-100 6-2
H Me 100 -400 100
H Me 12-5-200 12 5
H AMe 0 8-200 0 8
H Me 12 5-200 100
Rt
L= C ZNNZC'
N
T/C
0/
,0
at
Survi- opti-
vors muim
(out dos-
of 6) age
6 106
6 125
5 115
6 153
5 101
6 115
6 121
6 129
6 111
6 117
5 105
6 132
6 99
6 109
6 97
6 129
6 137
sC
SCH3
were prepared and tested for carcinostatic
activity. The structures of the square-
planar (VIII) and octahedral (IX) com-
plexes are shown below.
The screening data for the metal che-
lates of the Schiff bases (VI) are listed in
Table II. None of the metal chelates was
found to be toxic. Of the 17 screened, 10
displayed T/C values > 115. The metal
ions involved included rhodium(III),
SCH3 nickel(II), palladium(II), copper(II), and
zinc(II). Six metal chelates had T/C values
> 125, indicating considerable activity.
The nickel chelate (VIII; M - Ni, R
Me; R' - H) gave a T/C value of 153,
showing marked activity.
It is evident that metal chelates of the
tridentate Schiff bases (VI) have, in
general, greater cytotoxic activity than
those of the related bidentate Schiff bases
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(IV). One possible explanation is that the
former have a unidentate ligand, C1- or
NO3-, which is labile, especially since it
is trans to a nitrogen donor. Nitrogen
donors have a high "trans effect": they
labilize the ligands trans to them, causing
them to be readily displaced from the
metal complex (Basolo and Pearson,
1958). Rosenberg (1975) has enunciated a
number of "rules of thumb" relating to
the structural chemistry of metal com-
plexes displaying anti-tumour activity;
one of these rules is that the metal com-
plex should have one or more active
leaving (labile) groups, especially Cl- ion.
This preliminary survey has shown that
some transition metal chelates of Schiff
bases containing N and S donor atoms
possess cytotoxic activity. In particular,
several metal chelates of Schiff bases
containing the NNS donor grouping dis-
play marked activity. It is hoped that
further testing of these and other related
transition metal complexes may lead to a
useful anti-cancer drug.
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